Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Liabilities and Shareholders Equity (2021 - 2025)

Aligos Therapeutics' Liabilities and Shareholders Equity history spans 5 years, with the latest figure at $88.5 million for Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity rose 26.31% year-over-year to $88.5 million; the TTM value through Dec 2025 reached $483.7 million, up 22.38%, while the annual FY2025 figure was $88.5 million, 26.31% up from the prior year.
  • Liabilities and Shareholders Equity reached $88.5 million in Q4 2025 per ALGS's latest filing, down from $109.8 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $263.1 million in Q3 2021 to a low of $70.1 million in Q4 2024.
  • Average Liabilities and Shareholders Equity over 5 years is $149.6 million, with a median of $140.7 million recorded in 2022.
  • Peak YoY movement for Liabilities and Shareholders Equity: crashed 53.74% in 2024, then grew 26.31% in 2025.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $235.4 million in 2021, then crashed by 37.68% to $146.7 million in 2022, then grew by 3.3% to $151.5 million in 2023, then plummeted by 53.74% to $70.1 million in 2024, then increased by 26.31% to $88.5 million in 2025.
  • Per Business Quant, the three most recent readings for ALGS's Liabilities and Shareholders Equity are $88.5 million (Q4 2025), $109.8 million (Q3 2025), and $134.7 million (Q2 2025).